Jeroen J. Bax works in Cardiac Imaging affiliated with Leiden University.
Jeroen J. Bax is Professor of Cardiology and Director of Non-invasive Imaging and the Echo Laboratory at Leiden University Medical Center in the Netherlands. He is also Professor at the Turku PET Centre, University of Turku. He served as President of the European Society of Cardiology from 2016 to 2018 and completed his cardiology training at LUMC in 2002.
3,438 pubs · 217,290 cites · h-index 185
MD
Leiden University
1992
PhD
Vrije Universiteit Amsterdam
1996
Professor of Cardiology and Director of Non-invasive Imaging and Echo Laboratory
Leiden University Medical Center · 2006 - Present
Professor
Turku PET Centre, University of Turku
President
European Society of Cardiology · 2016 - 2018
JACCStassen et al.cohort
May support closer surveillance for low-flow moderate AS; extends discordant grading mortality associations from severe to moderate disease.
JACC. Cardiovascular imagingBär et al.cohort
AI lesion thresholds may refine ACS prediction on CCTA; leaves open prospective validation before clinical adoption.
Interventional / Structural Cardiology · Morristown Medical Center
Moderate aortic stenosis is not benign. These patients will benefit from further referral to a valve center for a comprehensive evaluation to establish the optimal management strategy. Rather than waiting for progression to severe aortic stenosis, PROGRESS supports TAVI for patients with moderate aortic stenosis and at-risk features.
New England Journal of MedicineGénéreux et al.
Interventional / Structural Cardiology · Morristown Medical Center
Moderate aortic stenosis is not benign. These patients will benefit from further referral to a valve center for a comprehensive evaluation to establish the optimal management strategy. Rather than waiting for progression to severe aortic stenosis, PROGRESS supports TAVI for patients with moderate aortic stenosis and at-risk features.
Journal of the American College of CardiologyGénéreux et al.
Sarrazyn et al.cohort
In patients with transthyretin cardiac amyloidosis, significant valvular heart disease—particularly multiple valvular lesions involving aortic stenosis—is strongly associated with an increased risk of heart failure hospitalization and all-cause mortality.
AmyloidSarrazyn et al.cohort
Significant valvular disease was associated with higher HF hospitalization or death risk in ATTR-CM; leaves open whether intervention improves outcomes.
EHJAnastasiou et al.cohort
Elevated RVGWW identifies higher event risk in acute HF with RV dysfunction; extends TAPSE stratification but remains hypothesis-generating pending validation.
EHJNg et al.cohort
Patients with combined moderate aortic and mitral regurgitation experience adjusted long-term mortality comparable to those with isolated severe aortic regurgitation, while severe aortic regurgitation combined with moderate or severe mitral regurgitation confers the worst survival.
EHJSanti et al.cohort
Echocardiographic evidence of elevated left atrial pressure independently predicts a two-fold higher risk of long-term mortality in asymptomatic patients with moderate-severe or severe chronic aortic regurgitation and preserved LVEF, offering a valuable tool to improve risk stratification.
EHJTang et al.cohort
Small aortic annulus was not associated with worse remodeling or mortality after TAVI; leaves open need for randomized confirmation before altering selection.
EHJAnastasiou et al.cohort
May aid pre-discharge risk stratification in acute HF; leaves open prospective validation before guiding therapy.
EHJDing et al.cross-sectional
CMD vessels show distinct plaque-remodeling phenotype with low resistance reserve; hypothesis-generating for epicardial-microvascular interplay, should not yet change practice.
EHJDing et al.cohort
In patients with early-stage CAD (TPV 1–250 mm³), AI-QCT measures of greater plaque volume, larger individual plaques, obstructive stenosis, and diffuse disease identify subgroups at substantially higher risk of MACE, potentially guiding earlier preventive strategies.
EHJAsarcıklı et al.cohort
May enhance HCM arrhythmic risk stratification when added to the ESC model; leaves open prospective validation before clinical adoption.
EHJKamila et al.cohort
May support PVAT attenuation as noninvasive marker of BAV inflammation; hypothesis-generating and requires prospective validation before clinical adoption.
EHJElmasry et al.cohort
RVD may support risk stratification in rheumatic mitral stenosis; extends independent prognostic data across medical and post-intervention settings.
EHJKamila et al.cohort
AI-guided quantitative coronary CT plaque assessment effectively stratifies cardiovascular risk in both diabetic and non-diabetic patients, revealing that diabetic patients experience higher event rates at comparable plaque volumes, particularly in moderate plaque stages.
EHJBar et al.cohort
AI-guided quantitative CT angiography identifies specific total and non-calcified plaque volume thresholds that strongly predict future acute coronary syndrome, even though 69% of future culprit lesions were non-obstructive at baseline.
EHJCaunīte et al.cohort
In STEMI patients, the presence of coronary artery ectasia is associated with less frequent stenting, higher need for urgent CABG, higher rates of suboptimal TIMI flow, and modestly worse LVEF driven by peak troponin levels and CABG requirement.
JACCStone et al.Guideline
Adoption of standardized endpoints will improve consistency across transcatheter mitral valve trials; extends VARC methodology to mitral regurgitation.
